Abstract

We have constructed and evaluated the utility of a helper-dependent virus vector system that is derived from Human Cytomegalovirus (HCMV). This vector is based on the herpes simplex virus (HSV) amplicon system and contains the HCMV orthologs of the two cis-acting functions required for replication and packaging of HSV genomes, the complex HCMV viral DNA replication origin (oriLyt), and the cleavage packaging signal (the a sequence). The HCMV amplicon vector replicated independently and was packaged into infectious virions in the presence of helper virus. This vector is capable of delivering and expressing foreign genes in infected cells including progenitor cells such as human CD34+ cells. Packaged defective viral genomes were passaged serially in fibroblasts and could be detected at passage 3; however, the copy number appeared to diminish upon serial passage. The HCMV amplicon offers an alternative vector strategy useful for gene(s) delivery to cells of the hematopoietic lineage.

Background

HCMV is a member of the betaherpesvirus family [42,48]. Other members of this family include human herpesvirus 6 (HHV-6), and human herpesvirus 7 (HHV-7), and all are widely distributed in human populations. During productive replication, the 230 kilobase pair (kbp) viral genome replicates by a rolling circle mechanism, which generates long head-to-tail concatemers that are cleaved to unit length and packaged in capsids. The state of the HCMV genome during latency remains unidentified and is likely to be circular and extrachromosomal [6]. The HCMV genome has been detected in cells within the hematopoietic lineage as early as CD34+ progenitors and up through differentiated macrophages [23,29,38,54].

Defective HSV viruses created by high multiplicity serial passage of virus stocks have been described on numerous occasions and have been characterized in detail at the molecular level [13,18,31,43,52,67]. Naturally occurring defective HSV viruses and laboratory derived HSV amplicon vectors are composed of head-to-tail tandem reiterations of subgenomic regions containing a functional origin of DNA replication (oriS or OriS) and a DNA cleavage/packaging signal [3,4,30,57,60-62]. These two cis-acting functions can be relatively small ranging from ca. 90–150 base pairs (bp) for the ori and ca. 250–300 bp for the a sequence. The functional HCMV oriLyt is much more complex than either of the HSV oris; the HCMV oriLyt consists of multiple direct and inverted repeats and extends over at least 1500 bp [1,2,24,37]. HCMV is
unique among the herpesviruses in not having an origin binding protein homolog that is required for DNA replication [45]. The HCMVα sequence varies in size from ca. 550 bp to 762 bp, however, the conserved pac-1 and pac-2 cis-elements which determine the sites for cleavage of replicated viral DNA are present [15,28,58,64,65].

In contrast to HSV, HCMV does not efficiently produce defective virus genomes, this difference may be related to the distinct biology of the two viruses [45]. However two reports described the identification of what may potentially be HCMV defective viruses created by serial high multiplicity passage [47,59]. These reports characterized HCMV defectives as very large subgenomic DNA molecules, in some cases extending over two thirds of the genome. In addition to these replication defective HCMV viruses, a recent report by Borst et al. 2003 [7], described the construction of an HCMV ampiclon. In this report we further utilized the HCMV ampiclon for gene delivery to human CD34+ cells.

HCMV infects cells of the hematopoietic lineage [34,38,39,55,68]. Viral genomes can be found in CD34+ cells from seropositive individuals and granulocyte-macrophage progenitors and differentiated macrophages can be infected experimentally [56]. We were interested in determining whether the tropism of HCMV can be exploited to construct defective HCMV virus vectors (amplicons) targeted to hematopoietic stem cells. The general feasibility of such an approach for other cell types has been shown using other herpesviruses, e.g. HSV, EBV, and HHV-7 [20,25,26,30,35,49,70,71].

Methods

Cells and virus

HCMV Toledo (passage 8, from Dr. S. Plotkin, Aventis Pasteur, Doylestown, PA) and HCMV Towne (passage 134, from Dr. Plotkin via Dr. Ed Mocarski, Stanford University), were propagated in human fibroblasts (HF) cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum (JRH Biosciences, Lenexa, Kans.). Recombinant HCMV, RC2.7EGFP, expressing enhanced green fluorescent protein (EGFP) (Clonetech, Palo Alto, CA), under the control of the major early 2.7 promoter, was constructed by cotransfection of plasmid pEAG2.7EGFP with a set of overlapping cosmids clones derived from HCMV Toledo (G.M. Duke, unpublished data).

Plasmid constructions

Plasmid pON205 (Spaete and Mocarski, 1985), contains the Towne strain α sequence, was obtained from Ed Mocarski (Stanford University). pEAG2.7EGFP was derived by cloning the EGFP gene from plasmid pEGFP-N2 (Clonetech, Palo Alto, CA) between the EagI and SmaI site of the β2.7 gene taken from Toledo (G.M. Duke, unpublished data). HCMV ampiclon plasmid Tn9-8 was derived by inserting the 6 kbp Dral fragment of TowneoriRIT (corresponding to nucleotides 91,166 – 95,909 relative to AD169) (Figure 1B), spanning the HCMV oriLyt into the Eco RI site of pON205. Tn9-8 was partially sequenced by single-cycle and multicyle dideoxy-nucleotide chain termination method of Sanger et al. [51]. The plasmids designated Tn9-8GF5 and Tn9-8GF7 incorporating the EGFP gene with the HCMV Major Immediate Early (MIE) promoter and SV40 poly A sequence was isolated as a 2,334 bp NsiI fragment from plasmid pEGFP-N2 (Clonetech, Palo Alto, CA), and cloned into the HCMV ampiclon Tn9-8 at the PstI site in both orientations. The gpt gene in Tn9-8-gpt was derived by cloning a PCR fragment from Escherichia coli DH5α using the primer pairs 5’CTGCAGCTAGTCTAGACTGGGACACTTCACATGAGC 3’and 5’CTGCAGCTATGTATCTAGAGCCAGGCGTTGAAAAGAT TA3’. Generation of viral stocks containing ampiclons

Plasmid DNA was transfected by CaPO4 precipitation of approximately 4 µg of Tn9-8 ampiclon DNA. The Tn9-8 DNA was transfected into approximately 1 × 106 passage 16 human fibroblast (HF) cells. At 24 hours post transfection, the cells were infected with CMV Towne at a multiplicity of infection (MOI) of 5 plaque forming units (PFU) per cell. Fresh medium was added to cells four days after infection and cells were harvested at 6 to 7 days post infection as described previously (Spaete and Frenkel, 1982). Virus stocks are prepared by three freeze-thaw cycles. Serial passages of ampiclon-containing viral stocks on fresh HF cells were superinfected with CMV Towne as a helper virus at a MOI of 1.

Southern blot analysis

Viral DNAs were digested with restriction enzyme, electrophoresed in 0.8% agarose gels, transferred to Hybond-N nylon membranes (Amersham Corp.), (Maniatis et al., 1989), and immobilized with a UV Crosslinker 1000 (Hoefer Scientific Instruments, San Francisco, CA). DNA on the membrane was probed with fluorescein-labeled pUC9 DNA using conditions previously described (Spaete and Mocarski, 1985).

Isolation of CD34+ cells and infection with CMV

The isolation of cord blood CD34+ stem cells was carried out by All Cells Inc. (Berkeley, CA) using CD34 Progenitor Cell Isolation Kit (Miltenyi Biotech, Auburn, CA). The positive selection of the CD34+ cells was carried out using hapten-conjugated antibody to CD34+ followed by anti-hapten antibody coupled to MACS Microbeads. The magnetically labeled cells are enriched on positive selection columns in the magnetic field. The purity of the CD34+
The population was >95% as analyzed by flow cytometry. The purified CD34+ cells were suspended in Iscove’s modified Dulbecco’s Minimal Essential Medium containing 5% fetal bovine serum. 2 × 10^5 CD34+ cells were used for each infection with TN9-8GF5 amplicon containing stocks, RC2.7EGFP virus, CMV Towne virus, or uninfected cell control. The cells mixed with virus were centrifuged at 500 × g for 10 mins at room temperature and were then placed in 37 °C water bath for one hour. Following this the cells were cultured in 6-well cell culture plates (Costar) for 18–72 hours. At the end of the incubation the cells were harvested for CD34 staining.

**EGFP expression and immunostaining for flow cytometric analysis**

Amplicon containing viral stocks prepared from passage 1 were used to infect HF or human CD34+ cells maintained in 12 well culture plates. At 24 hour intervals post infection, the wells were observed for EGFP expression with a Nikon TE2000 microscope under UV illumination. Immunostaining for CD34+ cells was done using Phycoerythrin (PE)-conjugated anti-CD34 antibody (Becton Dickinson, San Jose, CA). Infected or control cells were incubated with 20 µl of PE-labeled anti-CD34 antibody for 45 minutes at room temperature and subsequently were washed twice with PBS containing 0.1% BSA. The cells were directly analyzed for EGFP and CD34+ staining on a FACSCalibur instrument (Becton Dickinson, San Jose, CA), at 18 and 36 hours post infection.

**Results**

In order to exploit the natural tropism of HCMV for cells of the hematopoietic lineage, in a nonlytic manner, an HCMV amplicon i.e. a plasmid containing the HCMV ori-Lyt and a sequences was constructed. Theoretically, due to the large size of the HCMV genome, an amplicon derived...
from this virus should be able to carry the large DNA inserts and be capable of efficient introduction into hematopoietic cells by infection.

**Heterogeneity at oriLyt**

During analysis of cosmid clones of HCMV strain Towne, sequence heterogeneity was observed in the EcoRI E fragment of Towne that was not present in the Toledo strain [27]. The EcoRI E region spans in part the complex oriLyt region [1,2,24,37]. Sequences in a 1.2 kbp repeat fragment were shown to give rise to the heterogeneity observed at this locus in the Towne genome (Figure 1). The coordinates of a single repeat unit starts at nucleotide 94,561 relative to the AD169 sequence and end at nucleotide 95,807 [10]. This segment can repeat at least three times in Towne strains from different passage histories (Fig. 1). This heterogeneity is different from the 189 bp repeat region previously described for the Towne strain oriLyt which occurs near the BamHI sites in Figure 1 (nt 93337–93525 relative to AD169), [11,12]. Since Towne replicates to relatively high titers in cell culture, it was deemed advantageous to incorporate this heterogeneity in the origin containing sequences to be used in the amplicon construct.

**Construction of the HCMV amplicon**

As a test of the feasibility of the system, an HCMV amplicon was constructed which incorporated the two cis-acting functions required for the propagation of the defective virus genomes in the presence of helper virus (Figure 2). HCMV amplicon plasmid Tn9-8 was derived by inserting the 6 kbp Dral fragment of Towne (corresponding to nucleotides 91,166–95,909 relative to AD169) [10] (Figure 1B), spanning the HCMV oriLyt into the EcoRI site of pON205. The resulting amplicon was designated Tn9-8 (Figure 2), and was partially sequenced to verify its structure.

**Generation of viral stocks containing amplicons**

As a test of the ability of this construct to function as an amplicon, plasmid Tn9-8 was transfected in human fibroblast (HF) cells, and subsequently infected with HCMV Towne strain at an MOI of 5 to provide helper virus replication functions. Seven days later, infected cells were harvested, sonicated, and viral stocks were prepared for passage to fresh HF cells. Fresh HF cells were infected with the progeny of the transfection/infection and incubated for 7 days. The DNA from these infected cells was harvested (designated passage 1), restricted with HindIII and DpnI, and Southern blotted [36]. Southern blot analyses of DNA demonstrated that Tn9-8 was susceptible to digestion with DpnI, consistent with replication of the plasmid in bacteria (Figure 3, lane 2). In contrast, Tn9-8 in infected cells was resistant to DpnI demonstrating that it had replicated in eucaryotic cells (Figure 3, lanes 3–5).

This observation is consistent with replication and packaging of Tn9-8 into infectious virions. These results demonstrate that foreign DNA sequences, exemplified by the plasmid pUC9, can be introduced into defective genomes that are packaged and propagated in serially passaged virus stocks. To examine whether these results were the consequence of amplicon replication and packaging or integration of the amplicon plasmid into the helper virus, DNA prepared from passage 1 infected cells was digested with Cla I, Xba I, Afl II and Dpn I. These enzymes digested the Towne helper virus DNA to fragments no larger than 13.6 kbp but do not cut within Tn9-8. The amplicon DNA was significantly larger than 23 kbp consistent with the amplicon being replicated as a concatamer (Figure 4). This result indicated that the high molecular weight DNA containing plasmid sequences was packaged independently and was not integrated into helper virus.

Packaged defective viral genomes derived from Tn9-8 or a derivative containing a selectable marker (Tn9-8-gpt), were serially passaged in HF cells. Defective viruses could be detected at passage 3 when probed with plasmid pUC9; however, the copy number appeared to diminish upon serial passage (not shown). Selection with mycophenolic acid on Tn9-8-gpt amplicons did not enhance recovery.

**Rescue of monomeric repeat units in bacteria**

Concatemeric DNA was prepared from passage 2 and 3 virus stocks containing the defective virus genomes (Tn9-8-gpt), digested with Pst I and Hind III, respectively, in order to analyze monomeric repeat units. The Hind III-digested DNA was circularized by ligation and used to transform E. coli bacteria to analyze structure and to demonstrate shuttle vector capability between eucaryotic and bacterial hosts. A number of plasmids prepared from the rescue attempt had a restriction enzyme pattern indistinguishable from the input (Fig. 5A, lanes 1 and 2). Other plasmids however exhibited the expected restriction pattern consistent with a head-to-tail amplification of the a sequence (lanes 3 and 4). Digestion with Nael produced a fragment of the predicted size of a unit length a sequence (762 bp), and this product hybridized with an a sequence specific probe (PstI-SgrAI fragment from Tn9-8), (Figs. 2 and 5B, lanes 3 and 4). This type of amplification has been readily seen in restriction enzyme digested DNA preparations of parental genomes of both HSV and HCMV [31,40,41,58,64,69] and has also been observed in HSV amplicons using Southern blot hybridizations [15].

**Expression of heterologous genes in an HCMV amplicon**

To demonstrate that the HCMV amplicon could be used as a vector system to support the expression of a foreign gene, EGFP under the transcriptional control of the HCMV major immediate early (MIE) promoter was used
as test reporter gene. Two resulting amplicon plasmids designated Tn9-8GF5 and Tn9-8GF7 both expressed EGFP following transfection of HF cells in the absence of helper virus, as expected (not shown). Packaged amplicons were generated by introduction of Tn9-8GF5 into cells and infecting with HCMV 24 hours later at an MOI of 5. Transfection-derived viral stocks were passaged onto fresh HF cells supplemented with Towne helper virus at an MOI of 1. Viral stocks prepared from passage 1 were used to infect HF cells and grown on 12-well tissue culture plates. A limited number (ca. 0.1%) of brightly fluorescing cells could be seen by microscopic examination at 24, 72 and 96

Figure 2
Schematic representation of the HCMV amplicon plasmids Tn9-8gpt, Tn9-8GF7 and Tn9-8GF5. The EGFP expression cassette was cloned in two orientations in the unique PstI site in Tn9-8. The gpt expression cassette was cloned between the unique PstI and HindIII sites.
hours post-infection (Figure 6). This demonstrates that a foreign gene can be expressed in the context of a HCMV amplicon viral stock in infected HF cells.

To test the utility of the HCMV amplicon in gene therapy or gene delivery, we used packaged amplicons in viral stocks to infect and deliver an expressed gene into human CD34+ progenitor cells. Viral stocks containing amplicons carrying EGFP under the transcriptional control of the HCMV major immediate early (MIE) promoter prepared from passage 0 and passage 1 were used to infect CD34+ cells derived from cord blood. Starting at 24 h after infection, CD34+ cells were examined for EGFP expression by fluorescent microscopy. EGFP expression was observed in TN9-8GF5 amplicon-infected CD34+ cells starting at 24 h post-infection. The cells remained positive for EGFP expression for more than 96 hrs, at which point the cells were terminated (Figure 6).

In a separate experiment, at 36 hours post infection, the cells were stained with PE-labeled anti-CD34 and analyzed for the CD34 marker and EGFP expression. EGFP expression was observed in the CD34+ population in the TN9-8GF5 amplicon (0.3%, 0.1%) (Figure 7a, &7b) or the CMV-EGFP virus (0.6%) (Figure 7c) at 36 hours post infection. The CMV Towne control-virus infected cells or uninfected CD34+ cell control were negative for EGFP expression (Figure 7d, &7e). A small population (7–12%) of the cells lost expression of the CD34+ marker upon in vitro culture. EGFP expression was also observed in a CD34(-) population infected with either TN9-8GF5 amplicon containing viral stocks (0.8%, 0.1%) or with the
CMV-EGFP virus, RC2.7EGFP (3.6%) (Figure 7a, 7b & 7c). The CMV Towne infected cells or uninfected control cell also had a significant CD34 negative population but were negative for EGFP expression (Figure 7d, and 7e). These results clearly demonstrate that CD34+ cells can be infected with replication competent or incompetent CMV vectors expressing a foreign gene.

**Conclusions**
We have shown that a replication-defective virus vector system that is derived from HCMV is capable of delivering
and expressing foreign genes in infected primary cells including progenitor stem cells such as human CD34+ cells. Further improvement and optimization of the system offers the potential to deliver gene-based therapies to multipotent cells.

**Advantages for use of the HCMV amplicon**

Foremost among the advantages of the vector system we have described is the potential ability to efficiently infect and deliver genetic information to hematopoietic stem cells (CD34+) and other dividing and non-dividing cell types which may support HCMV infection [34,38,39,55,68]. Genetic hematological disorders such as thalassemias and sickle-cell anemia and other hemoglobinopathies could therefore be targeted for therapy with this strategy. Another potential advantage for the system is that vector DNA could possibly be maintained as an episome with minimal concern for the potential consequences of random integration of vector DNA (i.e. activation of oncogenes or inactivation of tumor suppressor genes). In order to insure efficient segregation as an episome, the EBV latent replication origin, oriP, and the transactivator, EBNA-1, could be added as was previously shown for another hybrid herpesvirus vector [71]. However such a modification may not be necessary because HCMV genomes appear to be carried continuously in cells of hematopoietic origin in infected individuals. Yet another potential advantage as with other herpesviral vectors, is that the HCMV vector system should have the capacity for very large inserts.

**Infection of CD34+ cells with HCMV**

The infectivity of CD34+ cells from seropositive and seronegative subjects with HCMV has been tested both *in vivo* and *in vitro* [53]. Furthermore, hematopoietic stem cells are also reported as a site for HCMV latency. Efficient transduction of human CD34+ cells with retroviral and non-viral vectors has been unsatisfactory due to the lack of maintenance of high levels of expression of the transgene following engraftment of the engineered cells [16]. The HCMV MIE promoter may not be the right promoter for optimal expression in a CD34+ cells, since it has been shown that in the context of a lentiviral-based gene transfer system this promoter appeared to function less

![Fluorescent Microscopic Analysis of TN9-8GF5 amplicon infected cells](Image)
efficiently due to a cell-type specific expression defect [16]. The approaches to improving the efficiency of gene transfer into human cells have focused on improving gene delivery vectors and optimizing ex vivo culture conditions, which preserve the developmental properties of the stem cells [14,22]. Umbilical cord blood is recognized as a rich source of hematopoietic CD34+ stem cells [33]. In our experiments we used cord blood derived CD34+ cells for infection with HCMV amplicon containing stocks or HCMV-EGFP virus. However, bone marrow derived CD34+ cells have also been shown to be infectable in vitro with HCMV [34]. Gentry & Smith [21], reported a progressive loss of primitive cell properties including a reduction of CD34 expression upon in vitro culture of cord blood derived CD34+ cells. In a separate study, cord blood derived CD34+ cells cultured with IL-3 in vitro showed a progressive decline of the CD34+ population and more differentiated cells originating in the CD34(-) population [9]. In our experiments with >95% pure cord blood derived CD34+ cell population, a loss of CD34 expression in a small percent population (9–12%) of stem cells upon in vitro culture has been observed. EGFP expression was also seen in the CD34(-) population (Fig 7a, 7b, &7c). It is possible that HCMV infection of CD34 cells could...
induce cell differentiation and loss of primitive properties including reduction of CD34 expression.

Further studies of HCMV infection in CD34 cells will help in defining whether CD34+ infected cells undergo cell differentiation by increased expression of other markers such as CD33, CD38, HLA-DR or cytokines. It is also relevant to note here that HCMV virus carries homologous sequences for HLA-related and cytokine-related molecules and infection can induce cellular cytokines [5,8,19,32,44,46,50,66]. The HCMV amplicons contain only the cis-acting ori and packaging sequences, and have no structural gene sequences. However, amplicon containing viral stocks are a mixture with HCMV replication competent helper virus. HCMV induced cell-differentiating effect, if any, might be minimized using a helper virus-free amplicon system. In this regard, it should be possible to test a number of strategies to prepare helper virus-free stocks [17,63]. These preparations would be useful for therapeutic applications in immuno-compromised patients.

Competing Interests
The authors of this publication are supported financially by salary and shares of MedImmune Inc., during the completion of this work. A patent application has been filed with the United States Patent Office relating to the content of this manuscript. The authors have assigned all rights of ownership to MedImmune Inc. The authors declare that they have no other competing interest.

Authors’ Contributions
KM carried out the expression analysis in human fibroblasts and CD34 cells. MNP & GMD generated amplicon stocks and MNP did the 'a' sequence analysis. GWK provided critical intellectual input. RRS provided the original idea and experimental design as well as cloning of the amplicon, generation of amplicon stocks and Southern analysis.

References
1. Anders DG, Kacica MA, Pari G, Punturieri SM: Boundaries and structure of human cytomegalovirus ori/Lyt, a complex origin for lytic-phase DNA replication. J Virol 1992, 66:3373-3384.
2. Anders DG, Punturieri SM: Multicomponent origin of cytomegalo- virus lytic-phase DNA replication. J Virol 1991, 65:931-937.
3. Barnett JW, Epstein DA, Chan HW: Class I defective herpes simplex virus DNA as a molecular cloning vehicle in eucaryotic cells. J Virol 1983, 48:384-95.
4. Bear SE, Collberg-Poley AM, Court DL, Carter BJ, Enquist LW: Analysis of two potential shuttle vectors containing herpes simplex virus defective DNA. J Mol Appl Genet 1984, 2:471-84.
5. Beck S, Barrell B: An HCMV reading frame which has similarity with both the Y and C regions of the TCR gamma chain. DNA Seq 1991, 2:233-8.
6. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA: Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999, 93:394-8.
7. Borst EM, Messerlie M: Construction of a cytomegalovirus-based amplicon: a vector with a unique transfer capacity. Hum Gene Ther 2003, 14:859-70.
8. Browne H, Smith GSB, Minson T: A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 1990, 347:770-72.
9. Caux C, Favre C, Saeland S, Duver P, Mannion P, Durand I, Aubry JP, de Vinas JE: Sequential loss of CD34 and cll loss of CD34 and class II HMC antigens on purified cord blood hematopoietic progenitors cultured with IL-3: characterization of CD34+, HLA-DR+ cells. Blood 1989, 74:1287-94.
10. Chee MS, Bankier ATSB, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA III, Kozarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG: Analysis of the proteincoding content of the sequence of the human cytomegalovirus strain AD169. In Current Topics in Microbiology and Immunology Volume 154, Edited by: McDougall JK. Berlin: Springer-Verlag; 1992:125-169.
11. Chen Z, Sugano S, Watanabe S: A 189-bp repeat region within the human cytomegalovirus replication origin contains a sequence dispensable but irreplaceable with other sequences. Virology 1999, 258:240-248.
12. Chen Z, Watanabe S, Yessagi R: Strain-dependent differences in the human cytomegalovirus replication origin. Arch of Virology 1996, 141:1-30.
13. Clulow DM, Hayward GS: Tandem repeat defective DNA from the L segment of the HSV genome. In Herpesvirus DNA Series Edited by: Becker Y. The Hague: Martinus Nijhoff; 1981:107-128.
14. de Wynter EA, Emmerson AJ, Testa NG: Properties of peripheral blood and cord blood stem cells. Ballieres Clin Mater Res Clin Haematol 1999, 12:1-17.
15. Deiss LP, Frenkel N: Herpes simplex virus amplicon: cleavage of concatemeric DNA is linked to packaging and involves amplification of the terminally reiterated a sequence. J Virol 1986, 57:933-41.
16. Douglas JL, Lin WT, Panis ML, Veres G: Efficient human immunodeficiency virus-based vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy1/Liv model of human T cell lymphopoiesis. Hum Gene Ther 2001, 12:401-13.
17. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996, 70:7190-97.
18. Frenkel N, Locker H, Batterson W, Hayward GS, Roizman B: Anatomy of herpes simplex virus DNA. VI. Defective DNA origi-nates from the S component. J Virol 1976, 20:527-31.
19. Gao JL, Murphy PM: Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem 1994, 269:28539-42.
20. Geller AI, Yu L, Wang Y, Fraefel C: Helper virus-free herpes simplex virus I-plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Exp Neurol 1997, 148:94-102.
21. Gentry T, Smith C: Retroviral vector-mediated gene transfer into umbilical cord blood CD34+, CD34- cells. Exp Hematol Stem Cell Res 1999, 27(8):1244-54.
22. Goerner M, Roedklin B, Torok-Storb B, Heimfeld S, Kiem HP: Expansion and transduction of nonenriched human cord blood cells using HS-5 conditioned medium and FLT3-L. J Hematother Stem Cell Res 2000, 9:739-65.
23. Hahn G, Jones R, Mocarski ES: Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998, 95:3937-42.
24. Hamzeh FM, Lietsman PS, Gibson W, Hayward GS: Identification of the lytic origin of DNA replication in human cytomegalo-virus by a novel approach utilizing ganciclovir-induced chain termination. J Virol 1990, 64:6184-6195.
25. Ho DY: Amplicon-based herpes simplex virus vectors. Methods Cell Biol 1994, 43:191-210.
26. Jacobs A, Breastfield XO, Fraefel C: HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia 1999, 1:402-416.
27. Kemble G, Duke G, Winter R, Spaete R: Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996, 70:2044-48.
Genetic Vaccines and Therapy 2005, 3:1

http://www.gvtl-journal.com/content/3/1/1

Page 11 of 11

(page number not for citation purposes)